Open access
Jul 2026
Enzalutamide promotes an early plasticity-associated transcriptional state without terminal neuroendocrine differentiation in prostate cancer cells
It is suggested that enzalutamide preferentially enhances early lineage plasticity rather than bona fide NEPC differentiation and provide a framework for distinguishing adaptive transcriptional reprogramming from true neuroendocrine lineage conversion in treatment-emergent prostate cancer.
R. Watanabe, M. Chosei, Haruna Arai et al.
· Frontiers in Oncology · 0 citations